Currently, immunotherapy drugs that have been approved for the clinical treatment of HPV-positive malignant tumors include PD-1 inhibitors such as nivolumab and pembrolizumab, as well as PD-L1 inhibitors such as avelumab and durvalumab. This evidence concerns the gene CD274 and cancer.